Estrogen is essential for normal growth and differentiation in the mammary gland. It also supports growth of approximately 50% of primary breast cancers. For this reason, removal of estrogen or blocking of its action with the anti-estrogen, tamoxifen, is the main treatment for estrogen receptor alpha (ERalpha)-positive tumors. In 1996, when oncologists became aware of a second ER, ERbeta, there was some doubt as to whether this receptor would be of importance in breast cancer because the clinical consensus was that responsiveness to tamoxifen is related to the presence of ERalpha in breast cancer. Today we know that ERalpha and ERbeta have distinct cellular distributions, regulate separate sets of genes and can oppose each other's actions on some genes. We also know that ERbeta is widely expressed in both the normal and malignant breast and that there are proliferating cells in the breast which express ERbeta. In this review we summarize what is known about ERbeta in breast cancer and examine the possibility that ERbeta-selective ligands may well represent a useful class of pharmacological tools with a novel target, namely proliferating cells expressing ERbeta.

This article has been cited by other articles:

				S.-H. Chung, K. Wiedmeyer, A. Shai, K. S. Korach, and P. F. Lambert Requirement for Estrogen Receptor {alpha} in a Mouse Model for Human Papillomavirus-Associated Cervical Cancer Cancer Res., December 1, 2008; 68(23): 9928 - 9934. [Abstract] [Full Text] [PDF]

				E. Sonestedt, S. Borgquist, U. Ericson, B. Gullberg, G. Landberg, H. Olsson, and E. Wirfalt Plant foods and oestrogen receptor {alpha}- and {beta}-defined breast cancer: observations from the Malmo Diet and Cancer cohort Carcinogenesis, November 1, 2008; 29(11): 2203 - 2209. [Abstract] [Full Text] [PDF]

				E. C. Chang, T. H. Charn, S.-H. Park, W. G. Helferich, B. Komm, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Estrogen Receptors {alpha} and {beta} as Determinants of Gene Expression: Influence of Ligand, Dose, and Chromatin Binding Mol. Endocrinol., May 1, 2008; 22(5): 1032 - 1043. [Abstract] [Full Text] [PDF]

				S Borgquist, C Holm, M Stendahl, L Anagnostaki, G Landberg, and K Jirstrom Oestrogen receptors {alpha} and show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer J. Clin. Pathol., February 1, 2008; 61(2): 197 - 203. [Abstract] [Full Text] [PDF]

				J. M. Wang, L. Liu, and R. D. Brinton Estradiol-17 -Induced Human Neural Progenitor Cell Proliferation Is Mediated by an Estrogen Receptor -Phosphorylated Extracellularly Regulated Kinase Pathway Endocrinology, January 1, 2008; 149(1): 208 - 218. [Abstract] [Full Text] [PDF]

				K. Britt, A. Ashworth, and M. Smalley Pregnancy and the risk of breast cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 907 - 933. [Abstract] [Full Text] [PDF]

				C. Zhao, J. Matthews, M. Tujague, J. Wan, A. Strom, G. Toresson, E. W-F. Lam, G. Cheng, J.-A. Gustafsson, and K. Dahlman-Wright Estrogen Receptor {beta}2 Negatively Regulates the Transactivation of Estrogen Receptor {alpha} in Human Breast Cancer Cells Cancer Res., April 15, 2007; 67(8): 3955 - 3962. [Abstract] [Full Text] [PDF]

				J. T.E. Lim, A. K. Joe, M. Suzui, M. Shimizu, M. Masuda, and I. B. Weinstein Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. Clin. Cancer Res., June 1, 2006; 12(11): 3478 - 3484. [Abstract] [Full Text] [PDF]

				E. K. Keeton and M. Brown Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-{alpha} and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT Mol. Endocrinol., June 1, 2005; 19(6): 1543 - 1554. [Abstract] [Full Text] [PDF]

				K. F. Koehler, L. A. Helguero, L.-A. Haldosen, M. Warner, and J.-A. Gustafsson Reflections on the Discovery and Significance of Estrogen Receptor {beta} Endocr. Rev., May 1, 2005; 26(3): 465 - 478. [Abstract] [Full Text] [PDF]

				S. O. Lee, N. Nadiminty, X. X. Wu, W. Lou, Y. Dong, C. Ip, S. A. Onate, and A. C. Gao Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells Cancer Res., April 15, 2005; 65(8): 3487 - 3492. [Abstract] [Full Text] [PDF]

				C. Qiu, L. Shan, M. Yu, and E. G. Snyderwine Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine Carcinogenesis, April 1, 2005; 26(4): 763 - 769. [Abstract] [Full Text] [PDF]

				G. Cheng, Y. Li, Y. Omoto, Y. Wang, T. Berg, M. Nord, P. Vihko, M. Warner, Y.-S. Piao, and J.-A. Gustafsson Differential Regulation of Estrogen Receptor (ER){alpha} and ER{beta} in Primate Mammary Gland J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 435 - 444. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				V. Cappelletti, L. Celio, E. Bajetta, A. Allevi, R. Longarini, P. Miodini, R. Villa, A. Fabbri, L. Mariani, R. Giovanazzi, et al. Prospective evaluation of estrogen receptor-{beta} in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients Endocr. Relat. Cancer, December 1, 2004; 11(4): 761 - 770. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				C. Forster, S. Kietz, K. Hultenby, M. Warner, and J.-A. Gustafsson Characterization of the ER{beta}-/-mouse heart PNAS, September 28, 2004; 101(39): 14234 - 14239. [Abstract] [Full Text] [PDF]

				L Nakopoulou, A C Lazaris, E G Panayotopoulou, I Giannopoulou, N Givalos, S Markaki, and A Keramopoulos The favourable prognostic value of oestrogen receptor {beta} immunohistochemical expression in breast cancer J. Clin. Pathol., May 1, 2004; 57(5): 523 - 528. [Abstract] [Full Text] [PDF]

				C. Palmieri, E. W.-F. Lam, J. Mansi, C. MacDonald, S. Shousha, P. Madden, Y. Omoto, A. Sunters, M. Warner, J.-A. Gustafsson, et al. The Expression of ER{beta}cx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival Clin. Cancer Res., April 1, 2004; 10(7): 2421 - 2428. [Abstract] [Full Text] [PDF]

				G. Cheng, Z. Weihua, M. Warner, and J.-A. Gustafsson Inaugural Article: Estrogen receptors ER{alpha} and ER{beta} in proliferation in the rodent mammary gland PNAS, March 16, 2004; 101(11): 3739 - 3746. [Abstract] [Full Text] [PDF]

				A. Strom, J. Hartman, J. S. Foster, S. Kietz, J. Wimalasena, and J.-A. Gustafsson Estrogen receptor {beta} inhibits 17{beta}-estradiol-stimulated proliferation of the breast cancer cell line T47D PNAS, February 10, 2004; 101(6): 1566 - 1571. [Abstract] [Full Text] [PDF]

				S. L. Zheng, W. Zheng, B.-l. Chang, X.-O. Shu, Q. Cai, H. Yu, Q. Dai, J. Xu, and Y.-T. Gao Joint Effect of Estrogen Receptor {beta} Sequence Variants and Endogenous Estrogen Exposure on Breast Cancer Risk in Chinese Women Cancer Res., November 15, 2003; 63(22): 7624 - 7629. [Abstract] [Full Text] [PDF]

				N. R. Bianco, G. Perry, M. A. Smith, D. J. Templeton, and M. M. Montano Functional Implications of Antiestrogen Induction of Quinone Reductase: Inhibition of Estrogen-Induced Deoxyribonucleic Acid Damage Mol. Endocrinol., July 1, 2003; 17(7): 1344 - 1355. [Abstract] [Full Text] [PDF]

				R. Schiff, S. Massarweh, J. Shou, and C. K. Osborne Breast Cancer Endocrine Resistance: How Growth Factor Signaling and Estrogen Receptor Coregulators Modulate Response Clin. Cancer Res., January 1, 2003; 9(1): 447S - 454S. [Abstract] [Full Text] [PDF]

				C. Forster, S. Makela, A. Warri, S. Kietz, D. Becker, K. Hultenby, M. Warner, and J.-A. Gustafsson Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium PNAS, November 26, 2002; 99(24): 15578 - 15583. [Abstract] [Full Text] [PDF]

				S. Saji, Y. Omoto, C. Shimizu, M. Warner, Y. Hayashi, S.-i. Horiguchi, T. Watanabe, S.-i. Hayashi, J.-A. Gustafsson, and M. Toi Expression of Estrogen Receptor (ER) {beta}cx Protein in ER{alpha}-positive Breast Cancer: Specific Correlation with Progesterone Receptor Cancer Res., September 1, 2002; 62(17): 4849 - 4853. [Abstract] [Full Text] [PDF]